替格瑞洛单药与替格瑞洛联合阿司匹林在急性冠脉综合征患者经皮冠状动脉介入术后1至12个月的比较(ULTIMATE-DAPT):一项随机、安慰剂对照、双盲临床试验
该随机、安慰剂对照、双盲试验在58个中心纳入3400例经皮冠状动脉介入术后双联抗血小板治疗1个月无主要缺血或出血事件的急性冠脉综合征患者,比较替格瑞洛(90 mg 每日两次)联合阿司匹林(100 mg 每日一次)与替格瑞洛联合安慰剂从术后1个月至12个月(共11个月)的疗效与安全性。结果显示,替格瑞洛联合安慰剂组临床相关出血(BARC 2、3或5型)发生率为2.1%,低于替格瑞洛联合阿司匹林组的4.6%(HR 0.45,95%CI 0.30-0.66;p<0.0001);主要不良心脑血管事件发生率分别为3.6%与3.7%(绝对差-0.1%,95%CI -1.4%至1.2%;HR 0.98,95%CI 0.69-1.39;非劣效性p<0.0001,优效性p=0.89)。作者认为,在该人群中,双联抗血小板治疗1个月后停用阿司匹林并以替格瑞洛单药维持可带来更优的临床结局。
要点
- 急性冠脉综合征患者经皮冠状动脉介入术后双联抗血小板治疗1个月无事件,替格瑞洛单药组临床相关出血2.1%,低于替格瑞洛联合阿司匹林组的4.6%(HR 0.45,95%CI 0.30-0.66;p<0.0001)。
- 替格瑞洛单药组主要不良心脑血管事件3.6%,替格瑞洛联合阿司匹林组3.7%(绝对差-0.1%,95%CI -1.4%至1.2%;HR 0.98,95%CI 0.69-1.39;非劣效性p<0.0001,优效性p=0.89),达到非劣效。
- 研究纳入的是经皮冠状动脉介入术后双联抗血小板治疗1个月无主要缺血或出血事件的患者,替格瑞洛单药治疗从术后1个月至12个月(共11个月)。
- 作者认为,结合既往研究,该人群大多数患者可从双联抗血小板治疗1个月后停用阿司匹林、维持替格瑞洛单药治疗中获益。
适用人群与场景
- 年龄18岁及以上、急性冠脉综合征、完成IVUS-ACS研究且经皮冠状动脉介入术后双联抗血小板治疗1个月无主要缺血或出血事件的患者。
- 研究在58个中心(中国、意大利、巴基斯坦和英国)进行,患者经皮冠状动脉介入术使用当代药物洗脱支架,术后双联抗血小板治疗1个月无事件。
诊断标准与关键阈值
- 主要优效性终点为临床相关出血,定义为出血学术研究联合会(BARC)2、3或5型。
- 主要非劣效性终点为主要不良心脑血管事件,定义为心源性死亡、心肌梗死、缺血性卒中、明确的支架血栓形成或临床驱动的靶血管血运重建的复合终点。
- 非劣效界值为2.5个百分点,预期替格瑞洛联合阿司匹林组事件率为6.2%。
处置流程与药物剂量
- 随机分组后从经皮冠状动脉介入术后1个月至12个月(共11个月),口服替格瑞洛90 mg 每日两次联合口服阿司匹林100 mg 每日一次,或口服替格瑞洛90 mg 每日两次联合匹配的口服安慰剂。
- 两个共同主要终点序贯检验:先检验主要优效性终点(临床相关出血),达到后才进行主要不良心脑血管事件的假设检验。
- 所有主要分析均在意向治疗人群中进行。
研究设计与关键结果
- 这项随机、安慰剂对照、双盲临床试验在58个中心纳入3400例(97.0%)来自IVUS-ACS研究的3505例参与者,随机分为替格瑞洛联合阿司匹林组1700例和替格瑞洛联合安慰剂组1700例;3399例(>99.9%)完成12个月随访。
- 经皮冠状动脉介入术后1个月至12个月,临床相关出血在替格瑞洛联合安慰剂组发生35例(2.1%),在替格瑞洛联合阿司匹林组发生78例(4.6%)(HR 0.45,95%CI 0.30-0.66;p<0.0001)。
- 主要不良心脑血管事件在替格瑞洛联合安慰剂组发生61例(3.6%),在替格瑞洛联合阿司匹林组发生63例(3.7%)(绝对差-0.1%,95%CI -1.4%至1.2%;HR 0.98,95%CI 0.69-1.39;非劣效性p<0.0001,优效性p=0.89)。
- 研究于2019年9月21日至2022年10月27日入组。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照、双盲临床试验。
- 试验注册号:ClinicalTrials.gov,NCT03971500。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急性冠脉综合征经皮冠状动脉介入术后使用当代药物洗脱支架、双联抗血小板治疗1个月无事件的患者,从术后1个月至12个月改用替格瑞洛单药可降低临床相关出血,且主要不良心脑血管事件发生率与替格瑞洛联合阿司匹林相似。
- 作者认为,结合既往研究,该人群大多数患者可从双联抗血小板治疗1个月后停用阿司匹林、维持替格瑞洛单药治疗中获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Following percutaneous coronary intervention with stent placement to treat acute coronary syndromes, international clinical guidelines generally recommend dual antiplatelet therapy with aspirin plus a P2Y12 receptor inhibitor for 12 months to prevent myocardial infarction and stent thrombosis. However, data on single antiplatelet therapy with a potent P2Y12 inhibitor earlier than 12 months after percutaneous coronary intervention for patients with an acute coronary syndrome are scarce. The aim of this trial was to assess whether the use of ticagrelor alone, compared with ticagrelor plus aspirin, could reduce the incidence of clinically relevant bleeding events without an accompanying increase in major adverse cardiovascular or cerebrovascular events (MACCE).
METHODS: In this randomised, placebo-controlled, double-blind clinical trial, patients aged 18 years or older with an acute coronary syndrome who completed the IVUS-ACS study and who had no major ischaemic or bleeding events after 1-month treatment with dual antiplatelet therapy were randomly assigned to receive oral ticagrelor (90 mg twice daily) plus oral aspirin (100 mg once daily) or oral ticagrelor (90 mg twice daily) plus a matching oral placebo, beginning 1 month and ending at 12 months after percutaneous coronary intervention (11 months in total). Recruitment took place at 58 centres in China, Italy, Pakistan, and the UK. Patients were required to remain event-free for 1 month on dual antiplatelet therapy following percutaneous coronary intervention with contemporary drug-eluting stents. Randomisation was done using a web-based system, stratified by acute coronary syndrome type, diabetes, IVUS-ACS randomisation, and site, using dynamic minimisation. The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5). The primary non-inferiority endpoint was MACCE (defined as the composite of cardiac death, myocardial infarction, ischaemic stroke, definite stent thrombosis, or clinically driven target vessel revascularisation), with an expected event rate of 6·2% in the ticagrelor plus aspirin group and an absolute non-inferiority margin of 2·5 percentage points between 1 month and 12 months after percutaneous coronary intervention. The two co-primary endpoints were tested sequentially; the primary superiority endpoint had to be met for hypothesis testing of the MACCE outcome to proceed. All principal analyses were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03971500, and is completed.
FINDINGS: Between Sept 21, 2019, and Oct 27, 2022, 3400 (97·0%) of the 3505 participants in the IVUS-ACS study were randomly assigned (1700 patients to ticagrelor plus aspirin and 1700 patients to ticagrelor plus placebo). 12-month follow-up was completed by 3399 (>99·9%) patients. Between month 1 and month 12 after percutaneous coronary intervention, clinically relevant bleeding occurred in 35 patients (2·1%) in the ticagrelor plus placebo group and in 78 patients (4·6%) in the ticagrelor plus aspirin group (hazard ratio [HR] 0·45 [95% CI 0·30 to 0·66]; p<0·0001). MACCE occurred in 61 patients (3·6%) in the ticagrelor plus placebo group and in 63 patients (3·7%) in the ticagrelor plus aspirin group (absolute difference -0·1% [95% CI -1·4% to 1·2%]; HR 0·98 [95% CI 0·69 to 1·39]; pnon-inferiority<0·0001, psuperiority=0·89).
INTERPRETATION: In patients with an acute coronary syndrome who had percutaneous coronary intervention with contemporary drug-eluting stents and remained event-free for 1 month on dual antiplatelet therapy, treatment with ticagrelor alone between month 1 and month 12 after the intervention resulted in a lower rate of clinically relevant bleeding and a similar rate of MACCE compared with ticagrelor plus aspirin. Along with the results from previous studies, these findings show that most patients in this population can benefit from superior clinical outcomes with aspirin discontinuation and maintenance on ticagrelor monotherapy after 1 month of dual antiplatelet therapy.
FUNDING: The Chinese Society of Cardiology, the National Natural Scientific Foundation of China, and the Jiangsu Provincial & Nanjing Municipal Clinical Trial Project.
TRANSLATION: For the Mandarin translation of the abstract see Supplementary Materials section.
参考来源
- Ge Z, Kan J, Gao X, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024. PMID: 38599220. doi:10.1016/S0140-6736(24)00473-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。